|
US5994392A
(en)
|
1988-02-26 |
1999-11-30 |
Neuromedica, Inc. |
Antipsychotic prodrugs comprising an antipsychotic agent coupled to an unsaturated fatty acid
|
|
US20030068362A1
(en)
*
|
1993-02-22 |
2003-04-10 |
American Bioscience, Inc. |
Methods and formulations for the delivery of pharmacologically active agents
|
|
US20030073642A1
(en)
*
|
1993-02-22 |
2003-04-17 |
American Bioscience, Inc. |
Methods and formulations for delivery of pharmacologically active agents
|
|
US20030133955A1
(en)
*
|
1993-02-22 |
2003-07-17 |
American Bioscience, Inc. |
Methods and compositions useful for administration of chemotherapeutic agents
|
|
US5439686A
(en)
*
|
1993-02-22 |
1995-08-08 |
Vivorx Pharmaceuticals, Inc. |
Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor
|
|
US5972948A
(en)
*
|
1994-07-01 |
1999-10-26 |
Solvay Pharmaceuticals Gmbh |
Method of inhibiting hyperglycemia and pharmaceutical composition for use therein
|
|
US6231888B1
(en)
|
1996-01-18 |
2001-05-15 |
Perio Products Ltd. |
Local delivery of non steroidal anti inflammatory drugs (NSAIDS) to the colon as a treatment for colonic polyps
|
|
EP0914116B1
(en)
*
|
1996-05-22 |
2000-10-11 |
Protarga Inc. |
Compositions comprising conjugates of cis-docosahexaenoic acid and taxotere
|
|
US5795909A
(en)
*
|
1996-05-22 |
1998-08-18 |
Neuromedica, Inc. |
DHA-pharmaceutical agent conjugates of taxanes
|
|
US6576636B2
(en)
|
1996-05-22 |
2003-06-10 |
Protarga, Inc. |
Method of treating a liver disorder with fatty acid-antiviral agent conjugates
|
|
KR100330373B1
(ko)
*
|
1996-05-28 |
2002-11-07 |
주식회사한국신약 |
탁솔을 함유한 주사용 약제 조성물
|
|
US6440980B1
(en)
*
|
1996-09-17 |
2002-08-27 |
Avanir Pharmaceuticals |
Synergistic inhibition of viral replication by long-chain hydrocarbons and nucleoside analogs
|
|
IL132941A0
(en)
*
|
1997-05-21 |
2001-03-19 |
Univ Leland Stanford Junior |
Composition and method for enhancing transport across biological membranes
|
|
US8853260B2
(en)
*
|
1997-06-27 |
2014-10-07 |
Abraxis Bioscience, Llc |
Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
|
|
ZA986614B
(en)
*
|
1997-07-25 |
1999-01-27 |
Gilead Sciences |
Nucleotide analog composition
|
|
WO1999013872A1
(en)
|
1997-09-17 |
1999-03-25 |
Eisai Co., Ltd. |
Antimicrobials
|
|
US20040136915A1
(en)
*
|
1997-10-01 |
2004-07-15 |
Dugger Harry A. |
Buccal, polar and non-polar spray containing atropine
|
|
US20050287075A1
(en)
*
|
1997-10-01 |
2005-12-29 |
Dugger Harry A Iii |
Buccal, polar and non-polar spray or capsule containing drugs for treating pain
|
|
US20030077228A1
(en)
*
|
1997-10-01 |
2003-04-24 |
Dugger Harry A. |
Buccal, polar and non-polar spray or capsule containing drugs for treating endocrine disorders
|
|
US20030095927A1
(en)
*
|
1997-10-01 |
2003-05-22 |
Dugger Harry A. |
Buccal, polar and non-polar spray or capsule containing drugs for treating muscular and skeletal disorders
|
|
US20030077227A1
(en)
*
|
1997-10-01 |
2003-04-24 |
Dugger Harry A. |
Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the central nervous system
|
|
US20030082107A1
(en)
*
|
1997-10-01 |
2003-05-01 |
Dugger Harry A. |
Buccal, polar and non-polar spray or capsule containing drugs for treating an infectious disease or cancer
|
|
US20030095926A1
(en)
*
|
1997-10-01 |
2003-05-22 |
Dugger Harry A. |
Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the gastrointestinal tract or urinary tract
|
|
US20050180923A1
(en)
*
|
1997-10-01 |
2005-08-18 |
Dugger Harry A.Iii |
Buccal, polar and non-polar spray containing testosterone
|
|
US20090162300A1
(en)
*
|
1997-10-01 |
2009-06-25 |
Dugger Iii Harry A |
Buccal, polar and non-polar spray containing alprazolam
|
|
US7632517B2
(en)
*
|
1997-10-01 |
2009-12-15 |
Novadel Pharma Inc. |
Buccal, polar and non-polar spray containing zolpidem
|
|
US20030095925A1
(en)
*
|
1997-10-01 |
2003-05-22 |
Dugger Harry A. |
Buccal, polar and non-polar spray or capsule containing drugs for treating metabolic disorders
|
|
US20040141923A1
(en)
*
|
1997-10-01 |
2004-07-22 |
Dugger Harry A. |
Buccal, polar and non-polar spray containing alprazolam
|
|
US20030185761A1
(en)
*
|
1997-10-01 |
2003-10-02 |
Dugger Harry A. |
Buccal, polar and non-polar spray or capsule containing drugs for treating pain
|
|
US20040136914A1
(en)
|
1997-10-01 |
2004-07-15 |
Dugger Harry A. |
Buccal, polar and non-polar spray containing ondansetron
|
|
US20050163719A1
(en)
*
|
1997-10-01 |
2005-07-28 |
Dugger Harry A.Iii |
Buccal, polar and non-polar spray containing diazepam
|
|
US20040136913A1
(en)
*
|
1997-10-01 |
2004-07-15 |
Dugger Harry A. |
Buccal, polar and non-polar spray containing sumatriptan
|
|
ES2293875T3
(es)
*
|
1997-10-01 |
2008-04-01 |
Novadel Pharma Inc. |
Aerosol bucal no polar.
|
|
US20030077229A1
(en)
*
|
1997-10-01 |
2003-04-24 |
Dugger Harry A. |
Buccal, polar and non-polar spray or capsule containing cardiovascular or renal drugs
|
|
US20030190286A1
(en)
*
|
1997-10-01 |
2003-10-09 |
Dugger Harry A. |
Buccal, polar and non-polar spray or capsule containing drugs for treating allergies or asthma
|
|
US20050002867A1
(en)
*
|
1997-10-01 |
2005-01-06 |
Novadel Pharma Inc. |
Buccal, polar and non-polar sprays containing propofol
|
|
US20050281752A1
(en)
*
|
1997-10-01 |
2005-12-22 |
Dugger Harry A Iii |
Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the central nervous system
|
|
US6197764B1
(en)
|
1997-11-26 |
2001-03-06 |
Protarga, Inc. |
Clozapine compositions and uses thereof
|
|
US5955459A
(en)
*
|
1997-11-26 |
1999-09-21 |
Neuromedica, Inc. |
Fatty acid-antipsychotic compositions and uses thereof
|
|
US5977174A
(en)
*
|
1997-11-26 |
1999-11-02 |
Neuromedica, Inc. |
Cholinergic compositions and uses thereof
|
|
US6153653A
(en)
*
|
1997-11-26 |
2000-11-28 |
Protarga, Inc. |
Choline compositions and uses thereof
|
|
DE69922296T2
(de)
*
|
1998-01-13 |
2005-10-27 |
Daiichi Suntory Pharma Co., Ltd. |
Antibakterille zusammensetzung zur topischen anwendung, enthaltend faropenem
|
|
US6919076B1
(en)
|
1998-01-20 |
2005-07-19 |
Pericor Science, Inc. |
Conjugates of agents and transglutaminase substrate linking molecules
|
|
US6958148B1
(en)
*
|
1998-01-20 |
2005-10-25 |
Pericor Science, Inc. |
Linkage of agents to body tissue using microparticles and transglutaminase
|
|
UA65607C2
(uk)
|
1998-03-04 |
2004-04-15 |
Орто-Макнейл Фармацевтикал, Інк. |
Фармацевтична композиція (варіанти) та спосіб її приготування
|
|
FI980901A7
(fi)
*
|
1998-04-23 |
1999-10-24 |
Orion Yhtymae Oyj |
Levosimendaania säädellysti vapauttavia oraalisia koostumuksia
|
|
ES2559766T3
(es)
*
|
1998-05-18 |
2016-02-15 |
Takeda Pharmaceutical Company Limited |
Comprimidos disgregables en la boca
|
|
US7413759B2
(en)
*
|
1998-05-21 |
2008-08-19 |
Beech-Nut Nutrition Corporation |
Method of enhancing cognitive ability in infant fed DHA containing baby-food compositions
|
|
KR100634953B1
(ko)
*
|
1998-07-20 |
2006-10-17 |
스미스클라인 비참 코포레이션 |
에프로사르탄을 포함하는 생물학적으로 강화된 경구 고형투여 형태의 제제
|
|
DE69924381T2
(de)
*
|
1998-07-28 |
2006-04-20 |
Takeda Pharmaceutical Co. Ltd. |
Leicht zerfallende feste zubereitung
|
|
WO2000009133A1
(fr)
*
|
1998-08-10 |
2000-02-24 |
Asahi Kasei Kogyo Kabushiki Kaisha |
Preparations orales, a liberation prolongee, a base de chlorhydrate de fasudil
|
|
US8293277B2
(en)
*
|
1998-10-01 |
2012-10-23 |
Alkermes Pharma Ireland Limited |
Controlled-release nanoparticulate compositions
|
|
US20040013613A1
(en)
*
|
2001-05-18 |
2004-01-22 |
Jain Rajeev A |
Rapidly disintegrating solid oral dosage form
|
|
US20080213378A1
(en)
*
|
1998-10-01 |
2008-09-04 |
Elan Pharma International, Ltd. |
Nanoparticulate statin formulations and novel statin combinations
|
|
US8236352B2
(en)
|
1998-10-01 |
2012-08-07 |
Alkermes Pharma Ireland Limited |
Glipizide compositions
|
|
CA2346001C
(en)
*
|
1998-10-01 |
2003-12-30 |
Elan Pharma International, Limited |
Controlled release nanoparticulate compositions
|
|
US7521068B2
(en)
*
|
1998-11-12 |
2009-04-21 |
Elan Pharma International Ltd. |
Dry powder aerosols of nanoparticulate drugs
|
|
US6428814B1
(en)
*
|
1999-10-08 |
2002-08-06 |
Elan Pharma International Ltd. |
Bioadhesive nanoparticulate compositions having cationic surface stabilizers
|
|
US6652864B1
(en)
|
1998-12-21 |
2003-11-25 |
Asilomar Pharmaceuticals, Inc. |
Compounds for intracellular delivery of therapeutic moieties to nerve cells
|
|
US6787082B1
(en)
*
|
1999-01-29 |
2004-09-07 |
Takeda Chemical Industries, Ltd. |
Compressing mallet with coating treatment
|
|
US7235583B1
(en)
*
|
1999-03-09 |
2007-06-26 |
Luitpold Pharmaceuticals, Inc., |
Fatty acid-anticancer conjugates and uses thereof
|
|
CA2366723C
(en)
*
|
1999-03-09 |
2011-08-02 |
Protarga, Inc. |
Fatty acid-anticancer conjugates and uses thereof
|
|
US6475984B2
(en)
*
|
1999-04-29 |
2002-11-05 |
The Nemours Foundation |
Administration of leptin
|
|
EP2030620A1
(en)
*
|
1999-05-07 |
2009-03-04 |
Wockhardt Limited |
(s)-benzoquinolizine carboxylic acids and their use as antibacterial agents
|
|
WO2000067802A1
(en)
*
|
1999-05-10 |
2000-11-16 |
Protarga, Inc. |
Fatty acid-n-substituted indol-3-glyoxyl-amide compositions and uses thereof
|
|
US6197337B1
(en)
*
|
1999-05-10 |
2001-03-06 |
Kenneth Weisman |
Therapeutic uses of abarelix
|
|
US7175855B1
(en)
*
|
1999-05-27 |
2007-02-13 |
Pfizer Inc. |
Ziprasidone suspension
|
|
US20040115134A1
(en)
*
|
1999-06-22 |
2004-06-17 |
Elan Pharma International Ltd. |
Novel nifedipine compositions
|
|
EP2269654A3
(en)
|
1999-08-24 |
2011-04-13 |
Cellgate Inc. |
Enhancing drug delivery across and into epithelial tissues using oligo arginine moieties
|
|
US6730293B1
(en)
|
1999-08-24 |
2004-05-04 |
Cellgate, Inc. |
Compositions and methods for treating inflammatory diseases of the skin
|
|
US7229961B2
(en)
|
1999-08-24 |
2007-06-12 |
Cellgate, Inc. |
Compositions and methods for enhancing drug delivery across and into ocular tissues
|
|
US6669951B2
(en)
*
|
1999-08-24 |
2003-12-30 |
Cellgate, Inc. |
Compositions and methods for enhancing drug delivery across and into epithelial tissues
|
|
US6426367B1
(en)
*
|
1999-09-09 |
2002-07-30 |
Efa Sciences Llc |
Methods for selectively occluding blood supplies to neoplasias
|
|
EP1214067A1
(en)
*
|
1999-09-09 |
2002-06-19 |
EFA Sciences Llc |
Methods for treating cell proliferative disorders including cancer
|
|
US6541508B2
(en)
*
|
1999-09-13 |
2003-04-01 |
Nobex Corporation |
Taxane prodrugs
|
|
US6713454B1
(en)
*
|
1999-09-13 |
2004-03-30 |
Nobex Corporation |
Prodrugs of etoposide and etoposide analogs
|
|
US6380405B1
(en)
|
1999-09-13 |
2002-04-30 |
Nobex Corporation |
Taxane prodrugs
|
|
HK1049787B
(en)
|
1999-10-01 |
2014-07-25 |
Immunogen, Inc. |
Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
|
|
US6383511B1
(en)
*
|
1999-10-25 |
2002-05-07 |
Epicept Corporation |
Local prevention or amelioration of pain from surgically closed wounds
|
|
WO2001035974A2
(en)
*
|
1999-11-15 |
2001-05-25 |
Pharma Mar S.A. |
Aplidine treatment of cancers
|
|
AU2058701A
(en)
*
|
1999-12-02 |
2001-06-12 |
F. Hoffmann-La Roche Ag |
Esters of vitamin D3 and uses thereof
|
|
US6638906B1
(en)
|
1999-12-13 |
2003-10-28 |
Nobex Corporation |
Amphiphilic polymers and polypeptide conjugates comprising same
|
|
US6380253B1
(en)
*
|
2000-01-05 |
2002-04-30 |
Efa Sciences Llc |
Method of stabilizing and potentiating the action of anti-angiogenic substances
|
|
AU2001230994A1
(en)
|
2000-01-19 |
2001-07-31 |
The United States of America, represented by The Secretary, Department of Health & Human Services |
Use of pentosan polysulfate to treat certain conditions of the prostate
|
|
ATE432928T1
(de)
*
|
2000-02-02 |
2009-06-15 |
Univ Florida State Res Found |
C10-taxanester als antitumormittel
|
|
CO5280224A1
(es)
*
|
2000-02-02 |
2003-05-30 |
Univ Florida State Res Found |
Taxanos sustituidos con ester en c7, utiles como agentes antitumorales y composiciones farmaceuticas que los contienen
|
|
US6649632B2
(en)
|
2000-02-02 |
2003-11-18 |
Fsu Research Foundation, Inc. |
C10 ester substituted taxanes
|
|
US6730691B1
(en)
|
2000-02-10 |
2004-05-04 |
Miles A. Galin |
Uses of alpha adrenergic blocking agents
|
|
US6660750B2
(en)
|
2000-02-15 |
2003-12-09 |
University Of Iowa Research Foundation |
Flavopiridol methods and compositions for HIV therapy
|
|
US6452024B1
(en)
|
2000-02-22 |
2002-09-17 |
Chaichem Pharmaceuticals International |
Process for extraction and purification of paclitaxel from natural sources
|
|
US20030083342A1
(en)
*
|
2002-08-27 |
2003-05-01 |
Steele Ronald Edward |
Combination of organic compounds
|
|
US20040156872A1
(en)
*
|
2000-05-18 |
2004-08-12 |
Elan Pharma International Ltd. |
Novel nimesulide compositions
|
|
US6392055B1
(en)
|
2000-07-19 |
2002-05-21 |
The University Of Pittsburgh |
Synthesis and biological evaluation of analogs of the antimitotic marine natural product curacin A
|
|
US7198795B2
(en)
*
|
2000-09-21 |
2007-04-03 |
Elan Pharma International Ltd. |
In vitro methods for evaluating the in vivo effectiveness of dosage forms of microparticulate of nanoparticulate active agent compositions
|
|
US6884777B1
(en)
|
2000-11-14 |
2005-04-26 |
The Nemours Foundation |
Method for treating respiratory distress syndrome
|
|
JP2005500988A
(ja)
*
|
2001-03-23 |
2005-01-13 |
ルイトポルド・ファーマシューティカルズ・インコーポレーテッド |
脂肪族アミン薬物複合体
|
|
JP4634694B2
(ja)
*
|
2001-03-23 |
2011-02-16 |
ルイトポルド・ファーマシューティカルズ・インコーポレーテッド |
脂肪アルコール薬物複合体
|
|
US20020198228A1
(en)
*
|
2001-04-03 |
2002-12-26 |
Kaura Sita R. |
Composition and method for the treatment of respiratory desease
|
|
US20020198209A1
(en)
*
|
2001-05-03 |
2002-12-26 |
Allergan Sales Inc. |
Compositions having enhanced pharmacokinetic characteristics
|
|
WO2002089853A2
(en)
*
|
2001-05-03 |
2002-11-14 |
Allergan, Inc. |
Compositions having enhanced pharmacokinetic characteristics
|
|
US7425565B2
(en)
*
|
2002-05-09 |
2008-09-16 |
Cedars-Sinai Medical Center |
Use of benzothiopenes to treat and prevent prostate cancer
|
|
CA2354471A1
(en)
*
|
2001-07-31 |
2003-01-31 |
Florida State University Research Foundation, Inc. |
C10 ester substituted taxanes
|
|
CA2354486A1
(en)
*
|
2001-07-31 |
2003-01-31 |
Florida State University Research Foundation, Inc. |
C7 ester substituted taxanes
|
|
SG129990A1
(en)
*
|
2001-08-01 |
2007-03-20 |
Univ Florida State Res Found |
C10 ester substituted taxanes
|
|
SG125889A1
(en)
*
|
2001-08-01 |
2006-10-30 |
Univ Florida State Res Found |
C7 ester subsituted taxanes
|
|
US6852737B2
(en)
*
|
2001-08-06 |
2005-02-08 |
Recordati Ireland Limited |
Crude and crystalline forms of lercanidipine hydrochloride
|
|
AU2004201240B2
(en)
*
|
2001-09-27 |
2008-08-07 |
Bar Ilan University |
Conjugated Psychotropic Drugs and Uses Thereof
|
|
KR100996239B1
(ko)
*
|
2001-09-27 |
2010-11-23 |
바-일란 유니버시티 |
접합된 항-정신병 약물 및 그의 용도
|
|
US7544681B2
(en)
*
|
2001-09-27 |
2009-06-09 |
Ramot At Tel Aviv University Ltd. |
Conjugated psychotropic drugs and uses thereof
|
|
US6730667B2
(en)
*
|
2001-11-26 |
2004-05-04 |
William R. Deagle |
Iontophoresis disc pain blocker
|
|
KR100949318B1
(ko)
*
|
2001-11-29 |
2010-03-23 |
사운드 파마슈티칼스 인코퍼레이티드 |
화학요법의 바람직하지 않은 작용을 개선하기 위한 방법과조성물
|
|
EP1471902B1
(en)
*
|
2002-01-04 |
2014-07-02 |
Sound Pharmaceuticals Incorporated |
Compositions for use in methods for treating hearing loss
|
|
DE60332212D1
(de)
|
2002-02-04 |
2010-06-02 |
Elan Pharma Int Ltd |
Arzneistoffnanopartikel mit lysozym-oberflächenstabilisator
|
|
US20040101566A1
(en)
*
|
2002-02-04 |
2004-05-27 |
Elan Pharma International Limited |
Novel benzoyl peroxide compositions
|
|
JP2005525368A
(ja)
*
|
2002-03-04 |
2005-08-25 |
メディミューン，インコーポレーテッド |
インテグリンαｖβ３アンタゴニストをＨＭＧ−ＣｏＡ還元酵素阻害剤またはビスフォスフォネートと併用投与する障害の予防または治療方法
|
|
AU2003235931A1
(en)
*
|
2002-05-13 |
2003-11-11 |
Takata Seiyaku Co., Ltd. |
Vintoperol-containing medicinal composition for transdermal administration
|
|
US20040266776A1
(en)
*
|
2003-06-25 |
2004-12-30 |
Gil Daniel W. |
Methods of preventing and reducing the severity of stress-associated conditions
|
|
US20040002663A1
(en)
*
|
2002-06-26 |
2004-01-01 |
Reeves William H. |
Method and system for use in detecting a cancerous and precancerous pathology
|
|
WO2004006959A1
(en)
*
|
2002-07-16 |
2004-01-22 |
Elan Pharma International, Ltd |
Liquid dosage compositions of stable nanoparticulate active agents
|
|
US20040023935A1
(en)
*
|
2002-08-02 |
2004-02-05 |
Dey, L.P. |
Inhalation compositions, methods of use thereof, and process for preparation of same
|
|
US7273889B2
(en)
*
|
2002-09-25 |
2007-09-25 |
Innovative Drug Delivery Systems, Inc. |
NMDA receptor antagonist formulation with reduced neurotoxicity
|
|
US20040235811A1
(en)
*
|
2002-10-08 |
2004-11-25 |
Sepracor Inc. |
Fatty acid modified forms of glucocorticoids
|
|
US20040109826A1
(en)
*
|
2002-12-06 |
2004-06-10 |
Dey, L.P. |
Stabilized albuterol compositions and method of preparation thereof
|
|
CN1744905A
(zh)
*
|
2002-12-10 |
2006-03-08 |
百敖新纳斯有限公司 |
局部抗感染制剂
|
|
US7524515B2
(en)
*
|
2003-01-10 |
2009-04-28 |
Mutual Pharmaceuticals, Inc. |
Pharmaceutical safety dosage forms
|
|
EP1583539A2
(en)
*
|
2003-01-13 |
2005-10-12 |
Cedars-Sinai Medical Center |
Paricalcitol as a chemotherapeutic agent
|
|
US6759539B1
(en)
|
2003-02-27 |
2004-07-06 |
Chaichem Pharmaceuticals International |
Process for isolation and purification of paclitaxel from natural sources
|
|
US7811606B2
(en)
*
|
2003-04-16 |
2010-10-12 |
Dey, L.P. |
Nasal pharmaceutical formulations and methods of using the same
|
|
US9808471B2
(en)
*
|
2003-04-16 |
2017-11-07 |
Mylan Specialty Lp |
Nasal pharmaceutical formulations and methods of using the same
|
|
US8912174B2
(en)
*
|
2003-04-16 |
2014-12-16 |
Mylan Pharmaceuticals Inc. |
Formulations and methods for treating rhinosinusitis
|
|
WO2004093807A2
(en)
*
|
2003-04-22 |
2004-11-04 |
Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. |
Somatostatin vectors
|
|
JP5069463B2
(ja)
|
2003-04-25 |
2012-11-07 |
ギリアード サイエンシーズ， インコーポレイテッド |
抗ウイルス性ホスホネート類似物
|
|
EP1636335B1
(en)
*
|
2003-05-28 |
2012-07-11 |
Mito Tek, LLC |
Compositions and methods for inhibiting an isoform of human manganese superoxide dismutase
|
|
WO2005009446A1
(en)
*
|
2003-07-17 |
2005-02-03 |
Cotherix, Inc. |
Combination therapies for treatment of hypertension and complications in patients with diabetes or metabolic syndrome
|
|
US20060089374A1
(en)
*
|
2003-07-17 |
2006-04-27 |
Glenn Cornett |
Enantiomeric compositions of cicletanine, alone and in combination with other agents, for the treatment of disease
|
|
US20050187278A1
(en)
*
|
2003-08-28 |
2005-08-25 |
Pharmacia Corporation |
Treatment or prevention of vascular disorders with Cox-2 inhibitors in combination with cyclic AMP-specific phosphodiesterase inhibitors
|
|
CA2537180A1
(en)
*
|
2003-08-29 |
2005-03-10 |
Cotherix, Inc. |
Cicletanine in combination with oral antidiabetic and/or blood lipid-lowering agents as a combination therapy for diabetes and metabolic syndrome
|
|
US20050148534A1
(en)
*
|
2003-09-22 |
2005-07-07 |
Castellino Angelo J. |
Small molecule compositions and methods for increasing drug efficiency using compositions thereof
|
|
GB0322994D0
(en)
*
|
2003-10-01 |
2003-11-05 |
Novartis Ag |
Organic compounds
|
|
AU2004285037B2
(en)
*
|
2003-10-29 |
2010-07-22 |
Sonus Pharmaceuticals, Inc. |
Tocopherol-modified therapeutic drug compounds
|
|
US20080045559A1
(en)
*
|
2003-10-29 |
2008-02-21 |
Sonus Pharmaceuticals, Inc. |
Tocopherol-modified therapeutic drug compounds
|
|
JP4884228B2
(ja)
*
|
2003-10-30 |
2012-02-29 |
ザ リサーチ ファウンデーション オブ ステイト ユニバーシティ オブ ニューヨーク |
タキソイド−脂肪酸コンジュゲート及びその医薬組成物
|
|
GB0326180D0
(en)
*
|
2003-11-11 |
2003-12-17 |
Leuven K U Res & Dev |
Biocompatible coating of medical devices
|
|
PE20050693A1
(es)
|
2004-02-13 |
2005-09-27 |
Univ Florida State Res Found |
Taxanos sustituidos con esteres de ciclopentilo en c10
|
|
TW200540164A
(en)
|
2004-03-05 |
2005-12-16 |
Univ Florida State Res Found |
C7 lactyloxy-substituted taxanes
|
|
US20100009928A1
(en)
|
2004-03-29 |
2010-01-14 |
Cheng Jin Q |
Compositions including triciribine and taxanes and methods of use thereof
|
|
US20100028339A1
(en)
|
2004-03-29 |
2010-02-04 |
Cheng Jin Q |
Compositions including triciribine and trastuzumab and methods of use thereof
|
|
LT2574341T
(lt)
|
2004-03-29 |
2017-09-11 |
University Of South Florida |
Navikų ir vėžio efektyvus gydymas triciribino fosfatu
|
|
US20100009929A1
(en)
|
2004-03-29 |
2010-01-14 |
Cheng Jin Q |
Compositions including triciribine and bortezomib and derivatives thereof and methods of use thereof
|
|
US20110008327A1
(en)
|
2004-03-29 |
2011-01-13 |
Cheng Jin Q |
Compositions including triciribine and epidermal growth factor receptor inhibitor compounds or salts thereof and methods of use thereof
|
|
US20100173864A1
(en)
|
2004-03-29 |
2010-07-08 |
Cheng Jin Q |
Compositions including triciribine and one or more platinum compounds and methods of use thereof
|
|
GB0413730D0
(en)
*
|
2004-06-18 |
2004-07-21 |
Tillotts Pharma Ag |
A pharmaceutical composition and its use
|
|
GB0413729D0
(en)
*
|
2004-06-18 |
2004-07-21 |
Tillotts Pharma Ag |
A pharmaceutical composition and its use
|
|
ES2720618T3
(es)
|
2004-07-27 |
2019-07-23 |
Gilead Sciences Inc |
Análogos de fosfonato de compuestos de inhibidores de VIH
|
|
US20060154959A1
(en)
*
|
2005-01-13 |
2006-07-13 |
Navitas Pharma |
Combination therapies of cicletanine and carvedilol
|
|
PL1791904T3
(pl)
*
|
2004-09-24 |
2015-02-27 |
Univ Maryland |
Sposób leczenia zatrucia związkami fosforoorganicznymi
|
|
US9132135B2
(en)
*
|
2004-09-24 |
2015-09-15 |
University Of Maryland, Baltimore |
Method of treating organophosphorous poisoning
|
|
US20060122127A1
(en)
*
|
2004-11-17 |
2006-06-08 |
Cypress Bioscience, Inc. |
Methods for reducing the side effects associated with mirtzapine treatment
|
|
US20080096915A1
(en)
*
|
2005-01-13 |
2008-04-24 |
Greenberg Traurig LLP |
Compositions for the treatment of metabolic disorders
|
|
US20070141174A1
(en)
*
|
2005-01-13 |
2007-06-21 |
Navitas Pharma, Inc. |
Enantiomeric compositions of cicletanine, in combination with other agents, for the treatment of hypertension
|
|
EP1850667A4
(en)
|
2005-02-09 |
2010-04-28 |
Paul Q Anziano |
COMPOSITIONS AND METHODS FOR INHIBITING AN ISOFORM OF HUMAN MANGANE SUPEROXIDE DISMUTASE
|
|
KR20070113262A
(ko)
*
|
2005-03-08 |
2007-11-28 |
사운드 파마슈티칼스 인코퍼레이티드 |
암의 치료 방법 및 암 치료용 조성물
|
|
US20060216767A1
(en)
*
|
2005-03-22 |
2006-09-28 |
Saladax Biomedical Inc. |
Docetaxel immunoassay
|
|
EP1888728A4
(en)
|
2005-05-04 |
2010-07-14 |
Pronova Biopharma Norge As |
Fatty acid analogues, D.H. DHA DERIVATIVES FOR USE AS A MEDICAMENT
|
|
JP5284779B2
(ja)
*
|
2005-06-07 |
2013-09-11 |
ラモット・アット・テル・アビブ・ユニバーシテイ・リミテッド |
コンジュゲート化された向精神薬の新規な塩およびその調製方法
|
|
US20070105817A1
(en)
*
|
2005-11-09 |
2007-05-10 |
Jim Page |
Use of cicletanine and other furopyridines for treatment of systolic-predominant hypertension, isolated systolic hypertension, elevated pulse pressure, and general hypertension
|
|
CN1870631B
(zh)
*
|
2005-11-11 |
2010-04-14 |
华为技术有限公司 |
媒体网关的门控方法
|
|
JP2009515895A
(ja)
*
|
2005-11-14 |
2009-04-16 |
ピーター ディー． ウインチ |
注射用薬物および薬学的に許容されるその塩の着色溶液
|
|
EP1966192B1
(en)
*
|
2005-12-01 |
2012-10-17 |
Pfizer Products Inc. |
Pyrimidine derivatives for the treatment of abnormal cell growth
|
|
DK3184526T3
(en)
|
2005-12-13 |
2019-01-14 |
Incyte Holdings Corp |
PYRROLO [2,3-D] PYRIMIDINE DERIVATIVES AS A JANUS-KINASE INHIBITOR
|
|
CZ300305B6
(cs)
*
|
2005-12-20 |
2009-04-15 |
Heaton, A. S. |
Farmaceutická kompozice obsahující derivát taxanu se zlepšenou terapeutickou úcinností
|
|
JP2009533420A
(ja)
*
|
2006-04-13 |
2009-09-17 |
アクテリオン ファーマシューティカルズ リミテッド |
早期特発性肺線維症の治療
|
|
JP2009534387A
(ja)
*
|
2006-04-19 |
2009-09-24 |
ノヴァデル ファーマ インコーポレイテッド |
安定な含水アルコール性経口噴霧調剤物および方法
|
|
SI2020996T1
(sl)
*
|
2006-05-16 |
2012-03-30 |
Gilead Sciences Inc |
Postopek in sestavki za zdravljenje hematološkihmalignosti
|
|
FR2902659A1
(fr)
|
2006-06-23 |
2007-12-28 |
Pierre Fabre Medicament Sa |
Ester de dha et son utilisation dans le traitement et la prevention des maladies cardiovasculaires
|
|
WO2008010223A2
(en)
|
2006-07-17 |
2008-01-24 |
Ramot At Tel Aviv University Ltd. |
Conjugates comprising a psychotropic drug or a gaba agonist and an organic acid and their use in treating pain and other cns disorders
|
|
WO2008014456A2
(en)
*
|
2006-07-28 |
2008-01-31 |
Collegium Pharmaceutical, Inc. |
Combination therapy for otitis with antiseptic and ph adjustment
|
|
WO2008021242A2
(en)
*
|
2006-08-10 |
2008-02-21 |
The Research Foundation Of State University Of New York |
Fluorotaxoid-fatty acid conjugates and pharmaceutical compositions thereof
|
|
US20080051380A1
(en)
|
2006-08-25 |
2008-02-28 |
Auerbach Alan H |
Methods and compositions for treating cancer
|
|
JP5552313B2
(ja)
|
2006-11-01 |
2014-07-16 |
プロノヴァ・バイオファーマ・ノルゲ・アーエス |
脂質化合物
|
|
EP2125786B1
(en)
*
|
2006-12-21 |
2011-03-16 |
Pfizer Products Inc. |
Succinate salt of 2-((4-(1-methyl-4-(pyridin-4-yl)-1h-pyrazol-3-yl) phenoxy)methyl)quinoline
|
|
US20080171089A1
(en)
*
|
2006-12-22 |
2008-07-17 |
Blondino Frank E |
Stable anti-nausea oral spray formulations and methods
|
|
US20080312241A1
(en)
*
|
2007-01-03 |
2008-12-18 |
Gilead Sciences, Inc. |
Cicletanine and PKC inhibitors in the treatment of pulmonary and cardiac disorders
|
|
TWI384986B
(zh)
*
|
2007-01-17 |
2013-02-11 |
Lg Life Sciences Ltd |
抗病毒劑之順丁烯二酸單鹽以及含有該單鹽之醫藥組成物
|
|
BRPI0808354A2
(pt)
*
|
2007-03-09 |
2014-07-29 |
Novartis Ag |
Sais de 3-(1h-indol-3-il)-4-[2-(4-metil-piperazin-1-il)-quinazolin-4 -il]-pirrola-2,5-diona
|
|
US9220837B2
(en)
*
|
2007-03-19 |
2015-12-29 |
Insuline Medical Ltd. |
Method and device for drug delivery
|
|
WO2008141264A1
(en)
*
|
2007-05-10 |
2008-11-20 |
Novadel Pharma Inc. |
Anti-insomnia compositions and methods
|
|
WO2008150845A1
(en)
*
|
2007-05-31 |
2008-12-11 |
Vanderbilt University |
Screening for wnt pathway modulators and pyrvinium for the treatment of cance
|
|
EP2740731B1
(en)
*
|
2007-06-13 |
2016-03-23 |
Incyte Holdings Corporation |
Crystalline salts of the janus kinase inhibitor (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentylpropanenitrile
|
|
US8067632B2
(en)
*
|
2007-07-26 |
2011-11-29 |
The Board Of Trustees Of The Leland Stanford Junior University |
Process to produce prostratin and structural or functional analogs thereof
|
|
WO2009042766A1
(en)
*
|
2007-09-26 |
2009-04-02 |
Mount Sinai School Of Medicine |
Azacytidine analogues and uses thereof
|
|
US7985325B2
(en)
*
|
2007-10-30 |
2011-07-26 |
Novellus Systems, Inc. |
Closed contact electroplating cup assembly
|
|
AU2008334924A1
(en)
*
|
2007-12-12 |
2009-06-18 |
Ultimorphix Technolgies B.V. |
Solid forms of Tenofovir disoproxil
|
|
PE20091156A1
(es)
*
|
2007-12-17 |
2009-09-03 |
Astrazeneca Ab |
Sales de (3-{[[3-(6-amino-2-butoxi-8-oxo-7,8-dihidro-9h-purin-9-il)propil](3-morfolin-4-ilpropil)amino]metil}fenil)acetato de metilo
|
|
US8207369B2
(en)
|
2008-02-11 |
2012-06-26 |
Ramot At Tel-Aviv University Ltd. |
Conjugates for treating neurodegenerative diseases and disorders
|
|
US8242166B2
(en)
|
2008-03-31 |
2012-08-14 |
Florida State University Research Foundation, Inc. |
C(10) ethyl ester and C(10) cyclopropyl ester substituted taxanes
|
|
WO2010118365A1
(en)
*
|
2009-04-10 |
2010-10-14 |
Abraxis Bioscience, Llc |
Nanoparticle formulations and uses therof
|
|
WO2009126401A1
(en)
*
|
2008-04-10 |
2009-10-15 |
Abraxis Bioscience, Llc |
Compositions of hydrophobic taxane derivatives and uses thereof
|
|
US8088782B2
(en)
*
|
2008-05-13 |
2012-01-03 |
Astrazeneca Ab |
Crystalline 4-(3-chloro-2-fluoroanilino)-7 methoxy-6-{[1-(N-methylcarbamoylmethyl)piperidin-4-yl]oxy}quinazoline difumarate form A
|
|
US8835506B2
(en)
|
2008-06-05 |
2014-09-16 |
Stc.Unm |
Methods and related compositions for the treatment of cancer
|
|
US9085527B2
(en)
|
2008-07-08 |
2015-07-21 |
Catabasis Pharmaceuticals, Inc. |
Fatty acid acylated salicylates and their uses
|
|
NZ590075A
(en)
|
2008-07-08 |
2012-12-21 |
Gilead Sciences Inc |
citrate, malonate and succinate salts of the HIV inhibitor ethyl N-[(S)({ [(2R,5R)-5-(6-amino-9H-purin-9-yl)-4-fluoro-2,5-dihydrofuran-2-yl]oxy} methyl)phenoxyphosphinoyl]-L-alaninate
|
|
KR101708065B1
(ko)
|
2008-07-08 |
2017-02-17 |
카타베이시스 파마슈티칼즈, 인코포레이티드 |
지방산 아세틸화 살리실레이트 및 그 용도
|
|
PT3279195T
(pt)
*
|
2008-12-01 |
2020-09-29 |
Oyster Point Pharma Inc |
Síntese e novas formas de sal de (r)-5-((e)-2-pirrolidin- 3-ilvinil)pirimidina
|
|
US9145396B2
(en)
|
2008-12-01 |
2015-09-29 |
Targacept, Inc. |
Synthesis and novel salt forms of (R)-5-((E)-2-pyrrolidin-3ylvinyl)pyrimidine
|
|
BRPI0922871A2
(pt)
*
|
2008-12-11 |
2016-11-16 |
Biovista Inc |
metodos para o tratamento da esclerose múltipla usando pirazinoindóis tetracíclicos
|
|
KR20160064245A
(ko)
*
|
2008-12-18 |
2016-06-07 |
노파르티스 아게 |
1-［4-［1-(4-시클로헥실-3-트리플루오로메틸-벤질옥시이미노)-에틸］-2-에틸-벤질］-아제티딘-3-카르복실산의 헤미푸마레이트 염
|
|
US8993625B2
(en)
*
|
2009-03-11 |
2015-03-31 |
Stable Solutions Llc |
Method of mitigating adverse drug events using omega-3 fatty acids as a parenteral therapeutic drug vehicle
|
|
US9034389B2
(en)
|
2009-03-11 |
2015-05-19 |
Stable Solutions Llc |
Omega-3 enriched fish oil-in-water parenteral nutrition emulsions
|
|
AR076590A1
(es)
*
|
2009-05-19 |
2011-06-22 |
Vivia Biotech Sl |
Metodos para proveer pruebas medicinales personalizada ex vivo para neoplasmas hematologicos
|
|
WO2010135621A1
(en)
|
2009-05-22 |
2010-11-25 |
Incyte Corporation |
3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl]octane- or heptane-nitrile as jak inhibitors
|
|
WO2011028685A1
(en)
*
|
2009-09-01 |
2011-03-10 |
Incyte Corporation |
Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
|
|
CN102762211A
(zh)
|
2009-12-09 |
2012-10-31 |
拜欧利纳斯有限公司 |
改善认知功能的方法
|
|
SG182414A1
(en)
|
2010-01-08 |
2012-08-30 |
Catabasis Pharmaceuticals Inc |
Fatty acid fumarate derivatives and their uses
|
|
SMT201800137T1
(it)
|
2010-03-10 |
2018-07-17 |
Incyte Holdings Corp |
Derivati di piperidin-4-il azetidina come inibitori di jak1
|
|
PH12012502296B1
(en)
|
2010-05-21 |
2017-10-06 |
Incyte Holdings Corp |
Topical formulation for a jak inhibitor
|
|
US8916610B2
(en)
|
2010-09-22 |
2014-12-23 |
Ramot At Tel-Aviv University Ltd. |
Acid addition salt of a nortriptyline-GABA conjugate and a process of preparing same
|
|
ES2536415T3
(es)
|
2010-11-19 |
2015-05-25 |
Incyte Corporation |
Pirrolopiridinas y pirrolopirimidinas sustituidas heterocíclicas como inhibidores de JAK
|
|
SG190839A1
(en)
|
2010-11-19 |
2013-07-31 |
Incyte Corp |
Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors
|
|
US20120178813A1
(en)
|
2011-01-12 |
2012-07-12 |
Thetis Pharmaceuticals Llc |
Lipid-lowering antidiabetic agent
|
|
WO2012154554A1
(en)
*
|
2011-05-06 |
2012-11-15 |
Catabasis Pharmaceuticals, Inc. |
Fatty acid triterpene derivatives and their uses
|
|
WO2012177606A1
(en)
|
2011-06-20 |
2012-12-27 |
Incyte Corporation |
Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as jak inhibitors
|
|
CN102952138B
(zh)
*
|
2011-08-17 |
2016-07-06 |
上海特化医药科技有限公司 |
一种吡唑并嘧啶酮化合物的盐、多晶型物及其药物组合物、制备方法和应用
|
|
TW201313721A
(zh)
|
2011-08-18 |
2013-04-01 |
Incyte Corp |
作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物
|
|
UA111854C2
(uk)
|
2011-09-07 |
2016-06-24 |
Інсайт Холдінгс Корпорейшн |
Способи і проміжні сполуки для отримання інгібіторів jak
|
|
MX361757B
(es)
|
2011-09-19 |
2018-12-13 |
Orexo Ab |
Nueva composicion farmaceutica resistente al abuso para el tratamiento de la dependencia de opioides.
|
|
CA2873093A1
(en)
*
|
2012-05-07 |
2013-11-14 |
Cellixbio Private Limited |
Compositions and methods for treatment of neuromuscular disorders and neurodegenerative disorders
|
|
WO2013173720A1
(en)
|
2012-05-18 |
2013-11-21 |
Incyte Corporation |
Piperidinylcyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors
|
|
US9382187B2
(en)
|
2012-07-10 |
2016-07-05 |
Thetis Pharmaceuticals Llc |
Tri-salt form of metformin
|
|
US8765811B2
(en)
|
2012-07-10 |
2014-07-01 |
Thetis Pharmaceuticals Llc |
Tri-salt form of metformin
|
|
PE20151157A1
(es)
|
2012-11-15 |
2015-08-19 |
Incyte Corp |
Formas de dosificacion de ruxolitinib de liberacion sostenida
|
|
LT3489239T
(lt)
|
2013-03-06 |
2022-03-10 |
Incyte Holdings Corporation |
Jak inhibitoriaus gamybos būdai ir tarpiniai junginiai
|
|
UA120499C2
(uk)
|
2013-08-07 |
2019-12-26 |
Інсайт Корпорейшн |
Лікування захворювань із застосуванням лікарських форм з уповільненим вивільненням для інгібітора jak1
|
|
US10463684B2
(en)
|
2014-01-29 |
2019-11-05 |
Board Of Regents, The Uneversety Of Texas System |
Nucleobase analogue derivatives and their applications
|
|
CA2947741A1
(en)
|
2014-05-05 |
2015-11-12 |
Thetis Pharmaceuticals Llc |
Compositions and methods relating to ionic salts of peptides
|
|
WO2015184305A1
(en)
|
2014-05-30 |
2015-12-03 |
Incyte Corporation |
TREATMENT OF CHRONIC NEUTROPHILIC LEUKEMIA (CNL) AND ATYPICAL CHRONIC MYELOID LEUKEMIA (aCML) BY INHIBITORS OF JAK1
|
|
BR112016029476A2
(pt)
|
2014-06-18 |
2017-08-22 |
Thetis Pharmaceuticals Llc |
complexos de aminoácido mineral de agentes ativos
|
|
US9242008B2
(en)
|
2014-06-18 |
2016-01-26 |
Thetis Pharmaceuticals Llc |
Mineral amino-acid complexes of fatty acids
|
|
CN104225615B
(zh)
*
|
2014-09-24 |
2017-02-01 |
东南大学 |
一种紫杉醇类磷脂化合物、其药物组合物及应用
|
|
WO2016198971A1
(en)
*
|
2015-06-08 |
2016-12-15 |
Mohan M Alapati |
Compositions and methods for the treatment of hyperglycemia and metabolic syndrome
|
|
WO2017160687A1
(en)
*
|
2016-03-15 |
2017-09-21 |
Vitality Biopharma, Inc. |
Methods and compositions for the treatment of demyelinating disorders
|
|
US10130719B2
(en)
|
2016-06-03 |
2018-11-20 |
Thetis Pharmaceuticals Llc |
Compositions and methods relating to salts of specialized pro-resolving mediators
|
|
WO2018002673A1
(en)
|
2016-07-01 |
2018-01-04 |
N4 Pharma Uk Limited |
Novel formulations of angiotensin ii receptor antagonists
|
|
IL322013A
(en)
|
2016-07-29 |
2025-09-01 |
Janssen Pharmaceutica Nv |
Niraparib or its salts for use in the treatment of prostate cancer
|
|
PT3661937T
(pt)
|
2017-08-01 |
2021-09-24 |
Gilead Sciences Inc |
Formas cristalinas de ((s)-((((2r,5r)-5-(6-amino-9h-purin-9-il)-4-fluoro-2,5-dihidrofurano-2-il)oxi)metil)(fenoxi)fosforil)-l-alaninato de etil (gs-9131) para tratamento de infeções virais
|
|
WO2019113487A1
(en)
|
2017-12-08 |
2019-06-13 |
Incyte Corporation |
Low dose combination therapy for treatment of myeloproliferative neoplasms
|
|
IL276302B2
(en)
|
2018-01-30 |
2023-11-01 |
Incyte Corp |
Procedures for preparing [1-(3-fluoro-2-(trifluoromethyl(isonicotinyl}piperidine-4-one)
|
|
SMT202400306T1
(it)
|
2018-03-30 |
2024-09-16 |
Incyte Corp |
Trattamento dell'idrosadenite suppurativa utilizzando inibitori di jak.
|
|
MX2020010884A
(es)
*
|
2018-04-17 |
2021-02-26 |
Cardurion Pharmaceuticals Llc |
Sales de meglumina de tienopirimidinas.
|
|
JP2021530507A
(ja)
|
2018-07-18 |
2021-11-11 |
マンザニータ ファーマシューティカルズ，インク． |
神経細胞に抗がん剤を送達するためのコンジュゲート、その使用方法及び製造方法
|
|
WO2020018888A1
(en)
|
2018-07-20 |
2020-01-23 |
The Board Of Regents Of The University Of Oklahoma |
Antimicrobial peptides and methods of use
|
|
CN112512597A
(zh)
|
2018-07-26 |
2021-03-16 |
大日本住友制药肿瘤公司 |
用于治疗与acvr1表达异常相关的疾病的方法以及用于此的acvr1抑制剂
|
|
KR20210142152A
(ko)
*
|
2019-03-22 |
2021-11-24 |
인티그레이티드 나노테라퓨틱스 아이엔씨. |
스캐폴드 모이어티로부터 제조된 지질 접합체
|
|
CR20220280A
(es)
|
2019-11-22 |
2022-09-02 |
Incyte Corp |
Terapia de combinación que comprende un inhibidor de alk2 y un inhibidor de jak2
|
|
CN115135317A
(zh)
|
2020-01-22 |
2022-09-30 |
西洛斯治疗有限公司 |
减少nmda拮抗剂的副作用
|
|
US11833155B2
(en)
|
2020-06-03 |
2023-12-05 |
Incyte Corporation |
Combination therapy for treatment of myeloproliferative neoplasms
|
|
CN119606959A
(zh)
*
|
2024-12-26 |
2025-03-14 |
典晶医药(无锡)有限公司 |
Tazofelone与紫杉类药物的组合物在治疗实体瘤中的应用
|